Treatment of Organophosphorus Poisoning

Initial Management

• The American Heart Association recommends ensuring proper personal protective equipment (PPE) when caring for patients with organophosphate exposure to prevent contamination of caregivers 1, 2
• Immediate dermal decontamination for external exposure by removing contaminated clothing and copious irrigation with soap and water is recommended 2, 3
• Atropine should be administered immediately for severe poisoning manifestations such as bronchospasm, bronchorrhea, seizures, or significant bradycardia, with initial doses often higher than for typical bradycardia, and doubled every 5 minutes until full atropinization is achieved 1, 2
• Maintenance of atropinization can be achieved by an atropine infusion 4

Airway Management

• Early endotracheal intubation is recommended for life-threatening organophosphate poisoning, with observational data suggesting better outcomes with early intubation in significant organophosphate poisoning 2, 4, 5
• Neuromuscular blockers metabolized by cholinesterase (succinylcholine and mivacurium) should be avoided as they are not recommended for patients with organophosphate poisoning 4, 6

Seizure Management

• Benzodiazepines, such as diazepam or midazolam, should be administered to treat seizures and agitation in patients with organophosphate poisoning 1, 2, 4

Oxime Therapy

• Pralidoxime is reasonable for organophosphate poisoning, with a Class 2a recommendation and Level A evidence, and should be administered early to reactivate the acetylcholinesterase enzyme 2, 5
• The American Heart Association recommends that oximes should not be withheld when the class of poison is unknown 1, 2

Special Considerations

• Organophosphates can cause permanent inactivation of the acetylcholinesterase enzyme, while carbamates spontaneously dissociate from acetylcholinesterase 2, 7
• Patients should be monitored for delayed muscle weakness, which can follow the initial cholinergic crisis even as late as 4 days after acute exposure, and watched for complications such as myonecrosis, rhabdomyolysis, and renal damage due to calcium overload in skeletal muscle 6

Treatment of Organophosphate Poisoning with Pralidoxime (2-PAM)

Initial Management Protocol

• The American Heart Association recommends administering atropine immediately at 1-2 mg IV for adults (0.02 mg/kg for children), doubling the dose every 5 minutes until bronchorrhea, bronchospasm, and bradycardia resolve, in conjunction with pralidoxime therapy, as stated by the American Society of Anesthesiologists (ASA) 8, 9

Pralidoxime Administration

• The American Heart Association suggests an initial adult dose of pralidoxime: 1-2 g IV administered slowly, preferably by infusion, with a maintenance therapy of 400-600 mg/hour for adults or 10-20 mg/kg/hour for children 8

Mechanism of Action

• Pralidoxime reactivates acetylcholinesterase (AChE) that has been inhibited by organophosphate compounds by competing with the bond between organophosphates and AChE, allowing restoration of normal enzyme activity, as described by the American Society of Anesthesiologists (ASA) 9

Adjunctive Therapy

• The American Society of Anesthesiologists (ASA) recommends always administering atropine concurrently with pralidoxime, as pralidoxime alone is insufficient to manage respiratory depression, and considers benzodiazepines for anxiety, seizures, or to facilitate mechanical ventilation 9

Clinical Controversies and Considerations

• The American Heart Association still recommends the use of pralidoxime (Class 2a recommendation), despite some studies questioning its efficacy 8

Organophosphate Poisoning Management

Initial Management

• Personal protective equipment must be used when caring for patients with organophosphate exposure to prevent contamination of healthcare providers, and immediate dermal decontamination through removal of contaminated clothing and copious irrigation with soap and water is essential for external exposure, according to the American Heart Association guidelines 10
• Atropine should be administered immediately at 1-2 mg IV for adults (0.02-0.1 mg/kg for children), doubling the dose every 5 minutes until bronchorrhea, bronchospasm, and bradycardia resolve, as recommended by the American Heart Association 10
• Early endotracheal intubation is recommended for life-threatening organophosphate poisoning, as stated by the American Heart Association 10

Adjunctive Therapy

• Atropine must always be administered concurrently with pralidoxime, as pralidoxime alone is insufficient to manage respiratory depression, according to the American Heart Association guidelines 10
• Benzodiazepines should be administered to treat seizures and agitation in the setting of organophosphate poisoning, as recommended by the American Heart Association 10
• Avoid neuromuscular blockers metabolized by cholinesterase (succinylcholine and mivacurium), as advised by the American Heart Association 10

Clinical Evidence and Considerations

• The American Heart Association gives pralidoxime a Class 2a recommendation with Level A evidence for organophosphate poisoning, indicating a strong recommendation with high-quality evidence 10
• Pralidoxime is most effective when administered early, before "aging" of the phosphorylated enzyme occurs, as stated by the American Heart Association 10
• In carbamate poisoning, the role of pralidoxime is less clear, but should not be withheld when the class of poison is unknown, according to the American Heart Association guidelines 10

Treatment of Organophosphate Poisoning

Initial Management

• The American Heart Association recommends immediate administration of atropine, pralidoxime, and benzodiazepines, along with supportive care including decontamination, airway management, and close monitoring for at least 48-72 hours 11
• Immediate dermal decontamination through removal of contaminated clothing and copious irrigation with soap and water is essential for external exposure 11

Special Considerations

• Organophosphates form a covalent bond with acetylcholinesterase causing permanent inactivation ("aging"), while carbamates spontaneously dissociate 11
• Pralidoxime should not be withheld when the class of poison (organophosphate vs. carbamate) is unknown 11

Treatment Algorithm

• Securing airway, breathing, and circulation is crucial in the treatment of organophosphate poisoning 11

Organophosphate Poisoning Management

Introduction to Treatment

• The American Heart Association recommends atropine, pralidoxime, benzodiazepines, and supportive care with early intubation as the cornerstone treatments for organophosphate poisoning, with no established role for hemodialysis 12, 13

Pharmacokinetic Limitations of Hemodialysis

• Organophosphates are highly lipophilic compounds that rapidly distribute into tissues and bind covalently to acetylcholinesterase, making them poor candidates for extracorporeal removal 12
• The primary pathophysiology involves irreversible enzyme inhibition, rather than circulating toxin levels that could be dialyzed 12

Established Treatment Algorithm

• The American Heart Association guidelines recommend decontamination with PPE, atropine administration, early intubation, pralidoxime, and benzodiazepines as immediate interventions for organophosphate poisoning 12
• Atropine should be given 1-2 mg IV for adults immediately for severe manifestations, with doses doubled every 5 minutes until full atropinization 12
• Early intubation should be performed for life-threatening poisoning, avoiding succinylcholine and mivacurium 12

Critical Pitfalls to Avoid

• Delaying antidote administration while considering hemodialysis can be harmful, and time-critical interventions like atropine and pralidoxime must be given immediately 12
• Withholding oximes when the class of cholinesterase inhibitor is unknown is not recommended 12

Management of Tachycardia During Atropinization in Organophosphate Poisoning

Core Management Principle

• Atropine-induced tachycardia is an expected pharmacologic effect and is NOT a contraindication to continued atropine administration in organophosphate poisoning, with the therapeutic endpoint being control of life-threatening muscarinic symptoms, according to the American Heart Association 14
• Organophosphate poisoning produces both muscarinic effects and nicotinic effects, creating a mixed clinical picture, as noted by the American Heart Association 14
• The tachycardia observed may be from nicotinic receptor overstimulation from the organophosphate itself, as reported by the American Heart Association 14

Specific Dosing Algorithm

• Escalation of atropine dose should be done by doubling the dose every 5 minutes until bronchorrhea, bronchospasm, and bradycardia resolve, as recommended by the American Heart Association 14

Therapeutic Endpoints

• Monitor for signs of adequate atropinization, including dry lungs, adequate oxygenation, dry skin and mucous membranes, and mydriasis, as indicated by the American Heart Association 14

Pediatric Considerations

• In children, tachycardia is even less of a concern than in adults, and atropine should not be stopped in the presence of tachycardia in pediatric organophosphate poisoning, according to the American Society of Anesthesiologists 15
• Children require relatively higher atropine doses compared to standard pediatric resuscitation doses, as noted by the American Society of Anesthesiologists 15

Concurrent Essential Therapies

• Pralidoxime reverses nicotinic effects, including muscle weakness and potentially some tachycardia, that atropine cannot address, as reported by the American Heart Association 14
• Benzodiazepines should be given for seizures and agitation, as recommended by the American Society of Anesthesiologists and the American Heart Association 14, 15

Monitoring Strategy

• Continuous cardiac monitoring should be used to watch for dysrhythmias, as recommended by the American Heart Association 14
• Serial respiratory assessments should be done to auscultate for bronchorrhea resolution, as indicated by the American Heart Association 14

Organophosphorus Poisoning Management

Initial Treatment and Dosing

• Children require 0.02 mg/kg IV/IO initially, with a minimum dose of 0.1 mg and maximum single dose of 0.5 mg, according to the American Heart Association guidelines 16
• Higher doses may be used with organophosphate poisoning in children—the standard pediatric resuscitation doses are insufficient, as recommended by the American Heart Association 16

Atropine-Induced Fever in Organophosphate Poisoning

Mechanism and Clinical Context

• Repeated administration of atropine produces adverse central nervous system effects, including both hallucinations and fever, in patients with organophosphate poisoning 17, 18
• The American Heart Association gives atropine a Class 1 recommendation with Level A evidence for severe organophosphate poisoning, with atropine remaining the immediate first-line treatment for severe manifestations including bronchospasm, bronchorrhea, seizures, or significant bradycardia, regardless of fever risk 19

Distinguishing Fever Sources and Management

• Fever in organophosphate poisoning may have multiple etiologies beyond atropine, including nicotinic effects causing muscle fasciculations and increased metabolic activity, and aspiration pneumonia from bronchorrhea 19
• Never withhold or prematurely discontinue atropine due to fever, as inadequate atropinization leads to respiratory failure and death, and the risk of undertreating organophosphate poisoning far exceeds the risk of atropine-induced fever 19

Treatment Recommendations

• Always administer pralidoxime concurrently (Class 2a recommendation) as it addresses nicotinic effects that atropine cannot reverse, in patients with organophosphate poisoning 19
• Fever is an expected adverse effect with high-dose atropine therapy and does not indicate treatment failure, in patients with organophosphate poisoning 17, 19

Organophosphate Poisoning Complications

Musculoskeletal Complications

• The American Society of Anesthesiologists identifies severe myonecrosis as a potential complication of organophosphate poisoning, resulting from excessive acetylcholine accumulation causing calcium flux into skeletal muscle, leading to myocyte death 20
• Rhabdomyolysis with subsequent myoglobinuria can cause renal damage in patients with organophosphate poisoning, requiring monitoring of creatine kinase and potassium levels 20
• Treatment for rhabdomyolysis in organophosphate poisoning includes adequate hydration, forced diuresis, and urine alkalinization when urine turns reddish (from myoglobin, not hemoglobin) 20

Clinical Distinctions

• The reddish urine in organophosphate poisoning is from myoglobin (muscle breakdown), not hemoglobin (red blood cell destruction), which is a crucial clinical distinction that prevents misdiagnosis 20

Monitoring Parameters

• Creatine kinase and potassium should be monitored for rhabdomyolysis detection in patients with organophosphate poisoning 20

Role of Nasogastric Tube in Organophosphate Poisoning

Critical Safety Considerations

• Healthcare workers performing gastric lavage are at significant risk of secondary exposure from gastric contents and emesis containing organophosphates, with documented cases requiring atropine, pralidoxime, and even intubation for 24 hours 21, 22, 23
• Personal protective equipment is mandatory when handling contaminated gastric contents, as failure to use PPE has resulted in severe illness in healthcare workers 21, 22
• Never allow healthcare workers to handle gastric contents without PPE, as organophosphates in emesis and gastric aspirate can cause severe secondary poisoning 21, 22, 23

Organophosphate and Nerve Agent Poisoning Management

Initial Treatment and Dosing

• The American Heart Association recommends pralidoxime 2g IV as a loading dose, followed by continuous infusion to maintain therapeutic plasma levels, always in conjunction with aggressive atropine therapy, for suspected organophosphate or nerve agent poisoning 24
• Early endotracheal intubation for life-threatening poisoning, avoiding succinylcholine and mivacurium, is recommended 24
• Benzodiazepines, such as diazepam or midazolam, should be administered for seizures and agitation 24
• Immediate dermal decontamination with appropriate PPE is essential to prevent secondary exposure 24

Guideline Recommendations

• The American Heart Association gives pralidoxime a Class 2a recommendation with Level A evidence, meaning "it is reasonable to use" with high-quality evidence supporting its efficacy 24

Organophosphorus Poisoning Management

Atropine Administration

• The American Academy of Pediatrics recommends administering atropine 0.26 mg IV/IO immediately (0.02 mg/kg) to a 3-year-old child weighing 13 kg, then doubling the dose every 5 minutes until full atropinization is achieved, defined as clear lungs, dry skin, heart rate >80/min, and adequate blood pressure 25
• The initial dose of atropine is 0.26 mg IV/IO (0.02 mg/kg × 13 kg), with a minimum single dose of 0.1 mg and a maximum single dose of 0.5 mg per dose in children 25
• The escalation protocol for atropine involves doubling the dose every 5 minutes until bronchorrhea, bronchospasm, and bradycardia resolve, with expected total requirements of 10-20 mg in the first 2-3 hours for children with severe organophosphate poisoning 26

Concurrent Therapies

• The American Society of Anesthesiologists recommends administering diazepam 2.6 mg IV (0.2 mg/kg × 13 kg) or midazolam 0.65-1.3 mg IV (0.05-0.1 mg/kg × 13 kg) in fractionated doses for seizures or agitation in a 3-year-old child weighing 13 kg 25, 26
• The American Society of Anesthesiologists advises against using succinylcholine and mivacurium for intubation in organophosphate poisoning, as these neuromuscular blockers are metabolized by cholinesterase and are contraindicated 27

Pralidoxime Administration

• The American Society of Anesthesiologists recommends administering pralidoxime after atropine effects become apparent, with a loading dose of 325-650 mg IV (25-50 mg/kg × 13 kg) over 15-30 minutes, followed by continuous infusion at 130-260 mg/hour (10-20 mg/kg/hour) 26
• Pralidoxime must be given early, as the organophosphate-enzyme bond undergoes "aging" within minutes to hours, after which pralidoxime becomes ineffective 26

Atropine and Adjunctive Therapy Guidelines for Organophosphate Poisoning

Initial Atropine Dosing

• Adults should receive an immediate IV bolus of 1–2 mg atropine; children receive 0.02 mg/kg (minimum 0.1 mg, maximum 0.5 mg per dose). The dose is then doubled every 5 minutes until atropinization is achieved (clear lungs, dry skin, heart rate > 80 bpm, systolic BP > 80 mmHg, mydriasis). American Heart Association (AHA) recommendation 28.

Dose‑Escalation Protocol

• Aggressive escalation is required: double the atropine dose every 5 minutes (not a fixed‑dose schedule) until all atropinization endpoints are met. AHA guidance 28.
• Typical cumulative atropine requirements are 10–20 mg within the first 2–3 hours; some patients may need up to 50 mg in the first 24 hours. Observational data from the American Society of Anesthesiologists (ASA) 29.

Maintenance Infusion After Atropinization

• Once atropinization is achieved, continue atropine as a continuous infusion at 10–20 % of the total loading dose per hour, not exceeding 2 mg/h in adults. AHA protocol 28.

Pralidoxime and Benzodiazepine Co‑Therapy

• Pralidoxime should be given concurrently: 1–2 g IV loading dose for adults (25–50 mg/kg for children), followed by a continuous infusion of 400–600 mg/h for adults (10–20 mg/kg/h for children). AHA recommendation 28.
• For seizures or agitation, administer a benzodiazepine—diazepam 0.2 mg/kg or midazolam 0.05–0.1 mg/kg. AHA and ASA evidence [28][29].

Neuromuscular Blocker Contraindications

• Avoid succinylcholine and mivacurium because they are metabolized by cholinesterase and are contraindicated in organophosphate poisoning. ASA safety advisory 29.

Pralidoxime Use in Organophosphate Poisoning – Evidence‑Based Highlights

Timing of Administration

• Early administration is critical – the American Society of Anesthesiologists advises that pralidoxime should be given as soon as possible, ideally within minutes to a few hours after exposure, before the organophosphate‑acetylcholinesterase complex “ages” and becomes irreversible. 30
• Window for effectiveness varies by agent – for the nerve agent soman, aging occurs within minutes, whereas for many agricultural organophosphates (e.g., dimethoate) a therapeutic window of up to 24 h exists, but efficacy drops by roughly 50 % after 6 h. 30

Pharmacodynamics and Mechanism of Action

• Oxime‑mediated reactivation – pralidoxime competes with the covalent bond formed between organophosphate molecules and acetylcholinesterase at nicotinic receptors, thereby reactivating the enzyme and restoring normal neuromuscular transmission. 30
• Atropine does not reverse nicotinic toxicity – while atropine alleviates muscarinic effects, it has minimal impact on nicotinic‑mediated muscle paralysis and respiratory failure; only oximes such as pralidoxime can reverse these life‑threatening nicotinic effects. 30

Adjunctive Therapy Considerations

• High cumulative atropine doses are often required – patients typically need 10–20 mg of atropine in the first 2–3 h, with some cases requiring up to 50 mg within the first 24 h to achieve adequate antimuscarinic control. 30

Safety and Adverse‑Effect Profile

• Common adverse effects – the American Society of Anesthesiologists reports that pralidoxime may cause transient hypotension, reduced cardiac output, and autonomic ganglion blockade, especially when administered rapidly as a bolus. Other observed effects include dizziness, blurred vision, diplopia, headache, nausea, tachycardia, and muscle rigidity. 30
• Hepatic safety – mild, transient hepatic enzyme elevations have been observed with higher pralidoxime doses, but these changes are generally not clinically significant and do not necessitate dose modification. 30

Guideline and Society Recommendations

• American Society of Anesthesiologists endorsement – the society recommends pralidoxime as an essential therapy for reversing nicotinic receptor dysfunction in organophosphate poisoning, reflecting consensus based on pharmacokinetic and clinical outcome data. 30

Pralidoxime Dosing and Adjunctive Therapy for Organophosphate Poisoning

Adult Dosing Protocol

• Loading dose: Give 1–2 g of pralidoxime intravenously over 15–30 minutes as the initial bolus in adult patients with suspected organophosphate poisoning. Maintenance infusion: Follow with a continuous IV infusion of 400–600 mg per hour to keep plasma concentrations therapeutic. 31

Pediatric Dosing Protocol

• Loading dose: Administer 20–50 mg/kg of pralidoxime intravenously (maximum 2 g) over 15–30 minutes in children with suspected organophosphate exposure. Maintenance infusion: Continue with a continuous IV infusion of 10–20 mg/kg per hour. 31

Timing and Administration Principles

• Do not delay oxime therapy: Pralidoxime should be started as soon as organophosphate poisoning is suspected, even when the exact class of poison (organophosphate vs. carbamate) is not yet confirmed. 31

Mandatory Concurrent Therapies

• Atropine: Administer atropine concurrently—1–2 mg IV for adults (0.02 mg/kg for children, minimum 0.1 mg, maximum 0.5 mg per dose), doubling the dose every 5 minutes until bronchorrhea, bronchospasm, and bradycardia resolve. 31
• Benzodiazepines for seizures: Use diazepam 0.2 mg/kg IV or midazolam 0.05–0.1 mg/kg IV to control seizures or severe agitation associated with organophosphate toxicity. 31

Contraindicated Neuromuscular Blockers

• Avoid succinylcholine and mivacurium: These agents are metabolized by cholinesterase and should not be used in patients with organophosphate poisoning. 31

Guideline Recommendation and Evidence Strength

• The American Heart Association assigns pralidoxime a Class 2a recommendation with Level A evidence, indicating that its use is reasonable and supported by high‑quality data. 31

Loading Dose Administration of Pralidoxime in Organophosphate Poisoning

Adult Loading Dose

Pediatric Loading Dose

Route of Administration

Urgent Timing

Mandatory Concurrent Atropine Therapy

Transition to Maintenance Infusion

Contraindicated Neuromuscular Blockers

Duration of Pralidoxime Therapy

Monitoring for Adverse Effects

Evidence Quality and Guideline Strength

Pralidoxime Use in Acute Organophosphate Poisoning

Reconstitution and Route of Administration

• Pralidoxime should be reconstituted and diluted with sterile water for injection or normal saline (0.9 % sodium chloride) and administered intravenously or intra‑osseously; intramuscular injection is not recommended because it cannot achieve rapid therapeutic plasma concentrations. 34

Loading Dose Regimens

Adults

• Give an initial loading dose of 1–2 g intravenously over 15–30 minutes; a slow infusion is essential to avoid transient hypotension, autonomic instability, and other adverse effects. 34

Children (generic pediatric patients)

• Administer 20–50 mg/kg (maximum 2 g) intravenously over 15–30 minutes; the higher end of the range (≈50 mg/kg) is advised for more severely poisoned patients due to larger volume of distribution. 34

Continuous Infusion Maintenance

Adults

• After the loading dose, start a continuous infusion of 400–600 mg/hour (≈8–10 mg/kg/hour) to keep plasma concentrations above 4 µg/mL throughout the poisoning period; intermittent bolus dosing allows levels to fall below therapeutic thresholds within 1.5–2 hours. 34

Children (generic pediatric patients)

• Infuse 10–20 mg/kg/hour continuously; pharmacokinetic studies show wide variability in clearance (≈0.9 ± 0.5 L/h/kg) and volume of distribution (≈1.7–13.8 L/kg), with more severely poisoned patients often requiring the higher dose range. 34

Contraindications and Cautions

• No absolute contraindications exist for pralidoxime in confirmed or suspected organophosphate poisoning; the American Heart Association (AHA) advises that oximes should not be withheld even when the specific class of cholinesterase inhibitor is unknown. 34

Mandatory Concurrent Therapies

• Atropine must always be given alongside pralidoxime because pralidoxime reverses only nicotinic effects, whereas atropine controls muscarinic toxicity (bronchorrhea, bronchospasm, bradycardia).

  • Adults: 1–2 mg IV initially, doubling every 5 minutes until muscarinic signs resolve.
  • Children: 0.02 mg/kg IV (minimum 0.1 mg, maximum 0.5 mg per dose), doubling every 5 minutes until atropinization is achieved. 34

• Benzodiazepines for seizure control: diazepam 0.2 mg/kg IV or midazolam 0.05–0.1 mg/kg IV. 34

Contraindicated Neuromuscular Blocking Agents

• Succinylcholine and mivacurium must never be used for intubation in organophosphate poisoning because they are metabolized by cholinesterase, which is inhibited by the toxin. 34

Evidence Quality and Guideline Strength

• The American Heart Association assigns pralidoxime a Class 2a recommendation with Level A evidence (reasonable to use, supported by high‑quality data). Although one randomized controlled trial failed to show a mortality benefit, the recommendation remains due to clear biochemical reactivation of acetylcholinesterase and reversal of nicotinic effects. 34

Clinical Pitfalls to Avoid

• Intermittent bolus dosing leads to plasma levels dropping below therapeutic thresholds within 1.5–2 hours, leaving patients unprotected during prolonged absorption of lipophilic organophosphates. 34
• Delaying pralidoxime while awaiting laboratory confirmation allows enzyme “aging” and renders the antidote ineffective; treatment should start immediately based on clinical suspicion. 34
• Omitting concurrent atropine results in uncontrolled muscarinic toxicity; atropine administration is mandatory. 34
• Rapid IV push administration causes hypotension, tachycardia, and autonomic instability; infusion must be given over 15–30 minutes. 34

Organophosphate Poisoning: Atropine and Pralidoxime Management

Atropine as First‑Line Therapy

• The American Society of Anesthesiologists (ASA) recommends atropine as the gold‑standard treatment for organophosphate poisoning, supported by Class I, Level A evidence and without any absolute contraindications. 35

Dosing Guidance for Atropine

• In the acute phase, cumulative atropine doses commonly reach 10–20 mg within the first 2–3 hours, and some patients may require up to 50 mg over 24 hours to achieve adequate clinical control. 35

Combined Antidote Strategy

• The ASA guideline advises that pralidoxime should be administered together with atropine in organophosphate poisoning, because atropine reverses only muscarinic effects while pralidoxime addresses the life‑threatening nicotinic effects such as muscle paralysis and respiratory failure. 35

Decontamination and Secondary Exposure Prevention

Skin Decontamination

• Remove all contaminated clothing immediately and irrigate the skin thoroughly with soap and water; brush off any powdered chemicals with a gloved hand before irrigation to reduce secondary exposure risk. 36

Gastrointestinal Decontamination

• Do not perform gastric lavage or give activated charcoal unless specifically directed by poison‑control services, because these measures pose a significant risk of secondary exposure to healthcare workers and have not demonstrated improvement in patient outcomes. [36][37]

Oral Interventions

• Avoid giving anything by mouth (e.g., water, milk, activated charcoal) unless explicitly instructed by poison‑control personnel, as oral administration can provoke emesis and aspiration without proven benefit. [36][37]

Poison‑Control Contact

• Contact the national Poison Help hotline (800‑222‑1222 in the United States) for additional guidance, providing details of the exposure time, nature of the toxic agent, and product name. [36][37]38